The FDA expanded its approval of Addyi to treat low libido in postmenopausal women up to age 65. The approval will open up ...

The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), ...

Milestone Pharmaceuticals announced the FDA approval of prescription etripamil nasal spray for the treatment of acute ...

Up until now, women who’d surpassed menopause and were dealing with frustratingly low libido—a.k.a. hypoactive sexual desire ...

The B-cell depleting therapy is indicated for adults with generalized myasthenia gravis and anti-acetylcholine receptor or ...

Cytokinetics announced the FDA approval of aficamten to improve functional capacity and symptoms in adults with symptomatic ...

Cardamyst is supplied as a carton of 2 disposable nasal spray devices, each delivering 2 sprays containing a total of 70mg of etripamil.

The U.S. Food and Drug Administration recently approved two new oral medicines to treat the sexually transmitted infection ...

Dr Dana Rizk is Professor of Medicine in the Division of Nephrology at the University of Alabama at Birmingham (UAB) and a VOYXACT VISIONARY Study Investigator and Co-Chair of the Steering Committee.

On Dec. 15, Sprout Pharmaceuticals received approval to use its pill, Addyi (flibanserin), to treat low sexual desire in ...

The self-administered treatment rapidly converts patients into sinus rhythm and may reduce trips to the hospital.

Leishmaniasis remains a major neglected tropical disease in humans, driven by diverse Leishmania species transmitted by sand ...